Additional file 1 of Serious infections in ANCA-associated vasculitides in the biologic era: real-life data from a multicenter cohort of 162 patients

Additional file 1: Suppl. Table 1. Comparison of baseline characteristics according to the prescription of chemoprophylaxis against Pneumocystis jirovecii during the initial induction of the remission (n = 135)*. Suppl. Table 2. Comparison between patients who developed (n = 50) or not (n = 112) serious infections (SI). Suppl. Table 3. Uni- and multi-variate logistic regression analysis of factors associated with serious infections (SI). Suppl. Table 4. Comparison between patients who developed (n = 23) or not (n = 138) serious infections (SI) during the 1st year after diagnosis. Suppl. Table 5. Uni- and multi-variate logistic regression analysis of factors associated with serious infections (SI) during the 1st year after diagnosis. Suppl. Table 6. Comparison of patient characteristics treated with cyclophosphamide (CYC) or rituximab (RTX) based induction regimens.